Статья
Ингибиторы ангиотензин-превращающего фермента в терапии артериальной гипертонии: зофеноприл – классоспецифичные эффекты и дополнительные преимущества
Представлен обзор литературы, посвященный применению ингибиторов ангиотензин4превращающего фермента (ИАПФ) в лечении артериальной гипертонии (АГ). Обсуждаются механизмы влияния ИАПФ на окислительный стресс, эндотелиальную дисфункцию, метаболизм инсулина и глюкозы. Приведены данные о фармакологических свойствах зофеноприла и его назначении при АГ.
1. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
2. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part 1: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-6.
3. Pepine CJ, Celermajer DS, Drexler H. Vascular health as a therapeutic tagert in cardiovascular disease. University of Florida 1998; 42 р.
4. Busse R, Lamontagne D. Endothelium-derived bradykinin is responsible for the increase in calcium produced by angiotensin-converting enzyme inhibitors in human endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol 1991; 344: 126-9.
5. Scholkens BA, Unger T. ACE Inhibitors, Endothelial function and Atherosclerosis. Amsterdam Media Medica Publications. March 1993.
6. Creager MA, Roddy MA. Effects of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505.
7. Anderson TJ, Overhiser RW, Haber H, Charbonneau FA. Comparitive study of four anti-hypertensive agents on endothelial function in patients with coronary disease. JACC 1998; 31(2Suppl A): 327A. Abstract.
8. Mancini GBJ, Henry G, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
9. Чазов Е.И., Беленков Ю.Н., Оганов Р.Г. и др. Информационное письмо. ВНОК. Результаты исследования EUROPA: периндоприл показан больным стабильной ИБС. Фарматека 2004; 2: 14-5.
10. HOPE study. N Engl J Med 2000; 342: 145-53.
11. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.
12. Tikellis C, Wookey P, Candido R. Improved islet morphology after blockade of the rennin4angiotensin system in the ZDF rat. Diabetes 2004; 53: 989-97.
13. FolIi F, SaadMJA, Velloso L, et al. Crosstalk between insulin and angiotensin II Signaling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.
14. Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J 2003; 5: 13-8.
15. Opie LH, Schall R. Old antihypertensives and new diabets. J Hypertens 2004; 22: 1453-8.
16. The PEACE Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
17. Marzo A, Dal Bo L, Mazzucchelli P, et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittel-Forsch 1999; 49: 992-6.
18. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of Zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991; 18(4): 478-86.
19. Corseaux D, Ollivier V, Fontaine V. Hemostasis Imbalance in Experimental Hypertension. Molec Med 2002; 8(4): 169-78.
20. Subissi A, Evangelista S., Giachetti A. Preclinical Profile of Zofenopril: An angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Reviews 1999; 17(2): 115-33.
21. Cominacini L, Pasini AF, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15(10 Pt 1): 891-5.
22. De Nigris F, D’Armiento FP, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduces susceptibility of plasma LDL to «in vitro» oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81(243): 107-15, 115-6.
23. Scribner AW, Loscalzo J, Napoli C, et al. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 1997; 482: 95-9.
24. Buikema H, Monnink SH, Tio RA, et al. Comparison of Zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in experimental heart failure. Br J Pharmacol 2000; 130(8): 1999-2007.
25. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148(1): e5.
26. Gagnon C, Legault F, Geraldes P, et al. Inverse effects of ACE inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004; 97(3): 373-81.
27. Borghi C, Bacchelli S, Degli Esposti D, et al. A review of the angiotensin4converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5 (9): 1965-77.
28. Malacco E, Piazza S, Omboni S. Zofenopril versus lisinopril in the treatment of essential hypertension in elderly patients: a multicentre, randomized, double-blind study. Clin Drug Invest 2005; 25(3): 175-82.
29. Leonetti G, Rappelli A, Omboni S., Behalf of the Study Group. A similar 24 h blood pressure control is obtained by zofenopril and candesartan in essential hypertensive patients. Blood Pressure 2006; 15(Suppl 1): 18-26.
30. Zanchetti A, Parati G, Malacco E. Zofenopril plus Hydrochlorothiazide: Combination Therapy for the Treatment of Mild to Moderate. Hypertension Drugs 2006; 66(8): 1107-15.